Tekmira CEO Sheds New Light on Halted Cholesterol Rx Trial, RXi Continues to Define Pipeline
February 11, 2010
Tekmira CEO Sheds New Light on Halted Cholesterol Rx Trial, RXi Continues to Define Pipeline
RXi Pharmaceuticals' new CEO, however, offered no timing on when the firm may meet its previously disclosed goals for the year of selecting a lead product candidate or securing at least one corporate partnership.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Two RNAi Rx Shops See Strong Gains in Share Value Since the Start of Year
October 8, 2009 / Gene Silencing News - For Some RNAi Rx Shops, Industry Deals with Bigger Players are Par for the Course
August 20, 2009 / Gene Silencing News - People in the News: Paul Dorman, Curtis Lockshin
April 25, 2013 / Gene Silencing News - Tekmira Releases Phase I Cancer Drug Data, Plans Phase II Trial in Neuroendocrine Tumors
April 11, 2013 / Gene Silencing News - Following Private Placement, RXi Has Funds to Last into 2015
April 4, 2013 / Gene Silencing News